IL148782A0 - Drugs for the treatment of malignant tumours - Google Patents

Drugs for the treatment of malignant tumours

Info

Publication number
IL148782A0
IL148782A0 IL14878200A IL14878200A IL148782A0 IL 148782 A0 IL148782 A0 IL 148782A0 IL 14878200 A IL14878200 A IL 14878200A IL 14878200 A IL14878200 A IL 14878200A IL 148782 A0 IL148782 A0 IL 148782A0
Authority
IL
Israel
Prior art keywords
treatment
drugs
malignant tumours
compounds
formula
Prior art date
Application number
IL14878200A
Other languages
English (en)
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of IL148782A0 publication Critical patent/IL148782A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14878200A 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours IL148782A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
IL148782A0 true IL148782A0 (en) 2002-09-12

Family

ID=27484521

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14878200A IL148782A0 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
IL148782A IL148782A (en) 1999-10-25 2002-03-20 Drugs for the treatment of malignant tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148782A IL148782A (en) 1999-10-25 2002-03-20 Drugs for the treatment of malignant tissues

Country Status (21)

Country Link
EP (1) EP1224172B1 (uk)
JP (1) JP3950337B2 (uk)
KR (2) KR100674160B1 (uk)
AT (1) ATE358668T1 (uk)
AU (1) AU775057B2 (uk)
CA (1) CA2386775C (uk)
CZ (1) CZ298534B6 (uk)
DE (1) DE60034240T2 (uk)
DK (1) DK1224172T3 (uk)
EE (1) EE200200207A (uk)
ES (1) ES2280258T3 (uk)
HK (1) HK1049830A1 (uk)
HR (1) HRP20020353A2 (uk)
HU (1) HU229072B1 (uk)
IL (2) IL148782A0 (uk)
IS (1) IS2750B (uk)
NO (1) NO323320B1 (uk)
NZ (1) NZ518296A (uk)
SE (1) SE0002320D0 (uk)
UA (1) UA73748C2 (uk)
WO (1) WO2001030758A1 (uk)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
DK1773816T3 (en) 2004-06-24 2015-01-26 Vertex Pharma Modulators of ATP-binding cassette transporters
US7884208B2 (en) 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
AR061348A1 (es) 2006-06-12 2008-08-20 Teva Pharma Preparados estables de laquinimod
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
DK2234485T3 (da) 2007-12-20 2014-02-10 Teva Pharma Stabile laquinimod-præparater
AU2009288108B2 (en) 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
MX2013004169A (es) * 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
WO2014074381A1 (en) * 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
ES2631194T3 (es) * 2014-09-23 2017-08-29 Active Biotech Ab Quinolincarboxamidas para usar en el tratamiento del mieloma múltiple
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
AU2015348778B2 (en) * 2014-11-19 2020-12-24 Active Biotech Ab Quinoline carboxamides for use in the treatment of leukemia
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
JP2023519153A (ja) 2020-03-03 2023-05-10 アクティブ バイオテック エイビー 組合せ療法における使用のためのタスキニモドまたはその薬学的に許容される塩
US20230203003A1 (en) * 2020-05-21 2023-06-29 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
US20240091215A1 (en) 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
AU2022303084A1 (en) 2021-07-02 2024-01-25 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
UA73748C2 (en) 2005-09-15
HRP20020353A2 (en) 2005-10-31
EP1224172B1 (en) 2007-04-04
WO2001030758A1 (en) 2001-05-03
NZ518296A (en) 2003-06-30
AU1185101A (en) 2001-05-08
KR100597938B1 (ko) 2006-07-06
HUP0203238A2 (hu) 2003-01-28
SE0002320D0 (sv) 2000-06-21
JP2003512454A (ja) 2003-04-02
DE60034240T2 (de) 2007-12-20
EP1224172A1 (en) 2002-07-24
NO20021932D0 (no) 2002-04-24
CZ20021293A3 (cs) 2002-07-17
NO20021932L (no) 2002-06-21
NO323320B1 (no) 2007-03-12
HU229072B1 (en) 2013-07-29
HK1049830A1 (zh) 2003-05-30
JP3950337B2 (ja) 2007-08-01
DE60034240D1 (de) 2007-05-16
CA2386775C (en) 2004-07-13
IL148782A (en) 2007-05-15
IS6329A (is) 2002-04-02
AU775057B2 (en) 2004-07-15
KR20020043646A (ko) 2002-06-10
CA2386775A1 (en) 2001-05-03
IS2750B (is) 2011-08-15
EE200200207A (et) 2003-06-16
KR100674160B1 (ko) 2007-01-24
HUP0203238A3 (en) 2003-05-28
CZ298534B6 (cs) 2007-10-31
DK1224172T3 (da) 2007-08-13
ATE358668T1 (de) 2007-04-15
ES2280258T3 (es) 2007-09-16
KR20060054496A (ko) 2006-05-22

Similar Documents

Publication Publication Date Title
YU23202A (sh) Lekovi za tretman malignih tumora
IL148782A0 (en) Drugs for the treatment of malignant tumours
PL367682A1 (en) Dolastatin 10 derivatives
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
SE9904505D0 (sv) Novel compounds
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MY146279A (en) Compounds affecting glucokinase
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
GB0109122D0 (en) Novel compounds
ZA200110540B (en) Novel diphenyl-piperidine derivate.
PL342614A1 (en) Anticarcinogenic drugs
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
AU2002352708A1 (en) Cytotoxic agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
TW200634002A (en) Chemical compounds
GB9907571D0 (en) Compounds
NO20030420L (no) Medikament for immunoterapi av maligne tumorer
SE0004827D0 (sv) Therapeutic compounds
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed